Earlier this year, U.S. Senators Amy Klobuchar (D-MN) and Roger Wicker (R-MS) and Representatives Gus Bilirakis (R-FL) and Doris Matsui (D-CA), co-chairs of the bipartisan Rare Disease Congressional Caucus, introduced bipartisan, bicameral legislation to increase access to molecular diagnostic testing for rare cancer patients. The Finn Sawyer ACT will provide CMS (Medicare, Medicaid and CHIP) coverage for cancer patients to receive broad-spectrum molecular diagnostics at the time of their cancer diagnosis.
Finn Sawyer died of rhabdomyosarcoma a month before his fourth birthday. Finn was never offered broad-spectrum molecular diagnostics that could have identified life-saving modern treatments
The Finn Sawyer Access to Cancer Testing Act would:
- Mandate coverage for molecular diagnostics tests at the time of initial diagnosis for patients on Medicare, Medicaid and CHIP
- Coordinate an education and awareness program on genetic testing. This bill will create an education and awareness program in coordination with the Department of Health and Human Services and the Director of the National Human Genome Research Institute to educate physicians and the general public on the use of genomic testing and the role of genetic counselors.
Rein in Sarcoma and many other cancer organizations endorse The Finn Sawyer Access to Cancer Testing Act. Please consider signing a petition to show your support Sign Petition